BIIB:NSD-Biogen Inc (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 143.66

Change

-7.05 (-4.68)%

Market Cap

USD 20.57B

Volume

1.86M

Analyst Target

USD 305.39
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. It offers RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, and biosimilars. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; and Sage Therapeutics, Inc., as well as collaborations with Fujirebio to identify and develop biomarkers for tau pathology in the brain and Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-11 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

-1.75 (-2.30%)

USD 228.18B
AMGN Amgen Inc

-8.47 (-2.59%)

USD 162.78B
SNY Sanofi ADR

-0.61 (-1.03%)

USD 148.55B
GILD Gilead Sciences Inc

-2.78 (-2.37%)

USD 142.46B
GRFS Grifols SA ADR

-0.07 (-0.90%)

USD 7.13B
AMRN Amarin Corporation PLC

+0.01 (+1.12%)

USD 0.25B
MIRA MIRA Pharmaceuticals, Inc. Com..

N/A

USD 0.02B
SCLX Scilex Holding Company

-0.03 (-8.14%)

N/A
SCLXW Scilex Holding Company

N/A

N/A

ETFs Containing BIIB

UBIO 6.30 % 0.95 %

N/A

N/A
IBRN iShares Trust - iShares N.. 4.19 % 0.00 %

N/A

USD 3.90M
BTEC:SW iShares Nasdaq US Biotech.. 3.51 % 0.00 %

-0.04 (-0.92%)

N/A
MRND 2.44 % 0.00 %

N/A

N/A
FXH First Trust Health Care A.. 2.11 % 0.63 %

-1.41 (-0.92%)

USD 1.01B
IBBQ Invesco Nasdaq Biotechnol.. 2.06 % 0.00 %

-0.19 (-0.92%)

USD 0.04B
2B70:F iShares NASDAQ US Biotech.. 2.06 % 0.00 %

-0.14 (-0.92%)

USD 0.52B
SAGP The Advisorsa Inner Circl.. 1.97 % 0.00 %

-0.28 (-0.92%)

USD 0.04B
GVLU Tidal ETF Trust 0.51 % 0.00 %

-0.26 (-0.92%)

USD 0.18B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

-1.07 (-0.92%)

USD 0.06B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

+0.37 (+-0.92%)

USD 3.30M
FLAG 0.00 % 1.52 %

N/A

N/A
IBB iShares Biotechnology ETF 0.00 % 0.47 %

-1.85 (-0.92%)

USD 6.39B
MXDU 0.00 % 0.34 %

N/A

N/A
DQML 0.00 % 0.00 %

N/A

N/A
JAGG 0.00 % 0.07 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.20 (-0.92%)

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.17 (-0.92%)

N/A
BIOT:LSE L&G PHARMA BREAKTHROUGH G.. 0.00 % 0.00 %

-0.20 (-0.92%)

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.18 (-0.92%)

N/A
SCHZ Schwab U.S. Aggregate Bon.. 0.00 % 0.04 %

-0.09 (-0.92%)

USD 8.61B
VCSH Vanguard Short-Term Corpo.. 0.00 % 0.07 %

-0.12 (-0.92%)

USD 35.68B
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

-0.07 (-0.92%)

N/A
ZBIO Zenas BioPharma, Inc. Com.. 0.00 % 0.95 %

+0.19 (+-0.92%)

N/A
HEAL:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

-0.18 (-0.92%)

N/A
LUMV:LSE Ossiam US Minimum Varianc.. 0.00 % 0.00 %

-610.00 (-0.92%)

N/A
USMV:LSE Ossiam US Minimum Varianc.. 0.00 % 0.00 %

-6.58 (-0.92%)

USD 0.01B
XMWD:LSE Xtrackers MSCI World Swap.. 0.00 % 0.00 %

-1.38 (-0.92%)

N/A
MVUS:PA 0.00 % 0.00 %

N/A

N/A
SPMV:PA 0.00 % 0.00 %

N/A

N/A
CEM2:F 0.00 % 0.00 %

N/A

N/A
OSX2:F Ossiam Lux - Ossiam US Mi.. 0.00 % 0.00 %

N/A

N/A
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.21 (-0.92%)

USD 0.52B
CEM2:XETRA 0.00 % 0.00 %

N/A

N/A
OSX2:XETRA Ossiam US Minimum Varianc.. 0.00 % 0.00 %

-8.40 (-0.92%)

N/A
BIOT 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -6.06% 40% F 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.06% 40% F 50% F
Trailing 12 Months  
Capital Gain -37.56% 40% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -37.56% 40% F 27% F
Trailing 5 Years  
Capital Gain -46.57% 43% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -46.57% 43% F 23% F
Average Annual (5 Year Horizon)  
Capital Gain -5.85% 60% D- 26% F
Dividend Return -5.85% 60% D- 25% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 26.28% 50% F 68% D+
Risk Adjusted Return -22.27% 50% F 23% F
Market Capitalization 20.57B 50% F 96% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector